Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization

Table 2

Relevant glycoforms for PK by HILI-UPLC.

Brand	Batch	Hybrid (%)	High mannose (%)	Sialylated (%)
Herceptin	N35973	4.20 ± 0.18	4.40 ± 0.92	0.23 ± 0.09
	N35812	5.43 ± 0.22	3.14 ± 0.12	0.22 ± 0.03
	N36003	4.62 ± 0.18	4.34 ± 0.30	0.35 ± 0.11
Trastuzumab-Probiomed	TZPP12002	3.52 ± 0.11	2.27 ± 0.06	1.17 ± 0.15
	TZPP12003	3.64 ± 0.26	2.24 ± 0.17	1.29 ± 0.25
	TZPP14001	1.69 ± 0.07	1.50 ± 0.07	0.72 ± 0.02

Variation is presented as confidence interval at 95% ().